Cargando…

Delta radiomics analysis of Magnetic Resonance guided radiotherapy imaging data can enable treatment response prediction in pancreatic cancer

BACKGROUND: Magnetic Resonance Image guided Stereotactic body radiotherapy (MRgRT) is an emerging technology that is increasingly used in treatment of visceral cancers, such as pancreatic adenocarcinoma (PDAC). Given the variable response rates and short progression times of PDAC, there is an unmet...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomaszewski, M. R., Latifi, K., Boyer, E., Palm, R. F., El Naqa, I., Moros, E. G., Hoffe, S. E., Rosenberg, S. A., Frakes, J. M., Gillies, R. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672552/
https://www.ncbi.nlm.nih.gov/pubmed/34911546
http://dx.doi.org/10.1186/s13014-021-01957-5
_version_ 1784615377426186240
author Tomaszewski, M. R.
Latifi, K.
Boyer, E.
Palm, R. F.
El Naqa, I.
Moros, E. G.
Hoffe, S. E.
Rosenberg, S. A.
Frakes, J. M.
Gillies, R. J.
author_facet Tomaszewski, M. R.
Latifi, K.
Boyer, E.
Palm, R. F.
El Naqa, I.
Moros, E. G.
Hoffe, S. E.
Rosenberg, S. A.
Frakes, J. M.
Gillies, R. J.
author_sort Tomaszewski, M. R.
collection PubMed
description BACKGROUND: Magnetic Resonance Image guided Stereotactic body radiotherapy (MRgRT) is an emerging technology that is increasingly used in treatment of visceral cancers, such as pancreatic adenocarcinoma (PDAC). Given the variable response rates and short progression times of PDAC, there is an unmet clinical need for a method to assess early RT response that may allow better prescription personalization. We hypothesize that quantitative image feature analysis (radiomics) of the longitudinal MR scans acquired before and during MRgRT may be used to extract information related to early treatment response. METHODS: Histogram and texture radiomic features (n = 73) were extracted from the Gross Tumor Volume (GTV) in 0.35T MRgRT scans of 26 locally advanced and borderline resectable PDAC patients treated with 50 Gy RT in 5 fractions. Feature ratios between first (F1) and last (F5) fraction scan were correlated with progression free survival (PFS). Feature stability was assessed through region of interest (ROI) perturbation. RESULTS: Linear normalization of image intensity to median kidney value showed improved reproducibility of feature quantification. Histogram skewness change during treatment showed significant association with PFS (p = 0.005, HR = 2.75), offering a potential predictive biomarker of RT response. Stability analyses revealed a wide distribution of feature sensitivities to ROI delineation and was able to identify features that were robust to variability in contouring. CONCLUSIONS: This study presents a proof-of-concept for the use of quantitative image analysis in MRgRT for treatment response prediction and providing an analysis pipeline that can be utilized in future MRgRT radiomic studies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13014-021-01957-5.
format Online
Article
Text
id pubmed-8672552
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86725522021-12-15 Delta radiomics analysis of Magnetic Resonance guided radiotherapy imaging data can enable treatment response prediction in pancreatic cancer Tomaszewski, M. R. Latifi, K. Boyer, E. Palm, R. F. El Naqa, I. Moros, E. G. Hoffe, S. E. Rosenberg, S. A. Frakes, J. M. Gillies, R. J. Radiat Oncol Research BACKGROUND: Magnetic Resonance Image guided Stereotactic body radiotherapy (MRgRT) is an emerging technology that is increasingly used in treatment of visceral cancers, such as pancreatic adenocarcinoma (PDAC). Given the variable response rates and short progression times of PDAC, there is an unmet clinical need for a method to assess early RT response that may allow better prescription personalization. We hypothesize that quantitative image feature analysis (radiomics) of the longitudinal MR scans acquired before and during MRgRT may be used to extract information related to early treatment response. METHODS: Histogram and texture radiomic features (n = 73) were extracted from the Gross Tumor Volume (GTV) in 0.35T MRgRT scans of 26 locally advanced and borderline resectable PDAC patients treated with 50 Gy RT in 5 fractions. Feature ratios between first (F1) and last (F5) fraction scan were correlated with progression free survival (PFS). Feature stability was assessed through region of interest (ROI) perturbation. RESULTS: Linear normalization of image intensity to median kidney value showed improved reproducibility of feature quantification. Histogram skewness change during treatment showed significant association with PFS (p = 0.005, HR = 2.75), offering a potential predictive biomarker of RT response. Stability analyses revealed a wide distribution of feature sensitivities to ROI delineation and was able to identify features that were robust to variability in contouring. CONCLUSIONS: This study presents a proof-of-concept for the use of quantitative image analysis in MRgRT for treatment response prediction and providing an analysis pipeline that can be utilized in future MRgRT radiomic studies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13014-021-01957-5. BioMed Central 2021-12-15 /pmc/articles/PMC8672552/ /pubmed/34911546 http://dx.doi.org/10.1186/s13014-021-01957-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Tomaszewski, M. R.
Latifi, K.
Boyer, E.
Palm, R. F.
El Naqa, I.
Moros, E. G.
Hoffe, S. E.
Rosenberg, S. A.
Frakes, J. M.
Gillies, R. J.
Delta radiomics analysis of Magnetic Resonance guided radiotherapy imaging data can enable treatment response prediction in pancreatic cancer
title Delta radiomics analysis of Magnetic Resonance guided radiotherapy imaging data can enable treatment response prediction in pancreatic cancer
title_full Delta radiomics analysis of Magnetic Resonance guided radiotherapy imaging data can enable treatment response prediction in pancreatic cancer
title_fullStr Delta radiomics analysis of Magnetic Resonance guided radiotherapy imaging data can enable treatment response prediction in pancreatic cancer
title_full_unstemmed Delta radiomics analysis of Magnetic Resonance guided radiotherapy imaging data can enable treatment response prediction in pancreatic cancer
title_short Delta radiomics analysis of Magnetic Resonance guided radiotherapy imaging data can enable treatment response prediction in pancreatic cancer
title_sort delta radiomics analysis of magnetic resonance guided radiotherapy imaging data can enable treatment response prediction in pancreatic cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672552/
https://www.ncbi.nlm.nih.gov/pubmed/34911546
http://dx.doi.org/10.1186/s13014-021-01957-5
work_keys_str_mv AT tomaszewskimr deltaradiomicsanalysisofmagneticresonanceguidedradiotherapyimagingdatacanenabletreatmentresponsepredictioninpancreaticcancer
AT latifik deltaradiomicsanalysisofmagneticresonanceguidedradiotherapyimagingdatacanenabletreatmentresponsepredictioninpancreaticcancer
AT boyere deltaradiomicsanalysisofmagneticresonanceguidedradiotherapyimagingdatacanenabletreatmentresponsepredictioninpancreaticcancer
AT palmrf deltaradiomicsanalysisofmagneticresonanceguidedradiotherapyimagingdatacanenabletreatmentresponsepredictioninpancreaticcancer
AT elnaqai deltaradiomicsanalysisofmagneticresonanceguidedradiotherapyimagingdatacanenabletreatmentresponsepredictioninpancreaticcancer
AT moroseg deltaradiomicsanalysisofmagneticresonanceguidedradiotherapyimagingdatacanenabletreatmentresponsepredictioninpancreaticcancer
AT hoffese deltaradiomicsanalysisofmagneticresonanceguidedradiotherapyimagingdatacanenabletreatmentresponsepredictioninpancreaticcancer
AT rosenbergsa deltaradiomicsanalysisofmagneticresonanceguidedradiotherapyimagingdatacanenabletreatmentresponsepredictioninpancreaticcancer
AT frakesjm deltaradiomicsanalysisofmagneticresonanceguidedradiotherapyimagingdatacanenabletreatmentresponsepredictioninpancreaticcancer
AT gilliesrj deltaradiomicsanalysisofmagneticresonanceguidedradiotherapyimagingdatacanenabletreatmentresponsepredictioninpancreaticcancer